• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    4/12/24 12:31:01 PM ET
    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • PaxMedica (NASDAQ:PXMD) stock increased by 110.9% to $0.87 during Friday's regular session. The company's market cap stands at $6.4 million.
    • Q32 Bio (NASDAQ:QTTB) shares rose 23.89% to $29.5. The market value of their outstanding shares is at $351.9 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCCP) shares increased by 20.45% to $21.2.
    • SenesTech (NASDAQ:SNES) stock rose 19.95% to $0.89. The market value of their outstanding shares is at $4.5 million.
    • Rani Therapeutics Hldgs (NASDAQ:RANI) shares moved upwards by 17.48% to $5.25. The market value of their outstanding shares is at $136.7 million.
    • Allarity Therapeutics (NASDAQ:ALLR) shares moved upwards by 16.92% to $2.69. The company's market cap stands at $1.2 million.

    Losers

    • Motus GI Hldgs (NASDAQ:MOTS) shares declined by 39.0% to $0.26 during Friday's regular session. The company's market cap stands at $1.3 million.
    • Monogram Orthopaedics (NASDAQ:MGRM) shares declined by 25.31% to $3.04. The market value of their outstanding shares is at $96.1 million.
    • BioSig Technologies (NASDAQ:BSGM) shares decreased by 20.15% to $1.19. The company's market cap stands at $11.1 million.
    • Rallybio (NASDAQ:RLYB) shares fell 20.14% to $2.38. The market value of their outstanding shares is at $98.6 million.
    • Portage Biotech (NASDAQ:PRTG) shares fell 18.01% to $0.41. The company's market cap stands at $8.1 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock decreased by 14.1% to $2.56. The market value of their outstanding shares is at $10.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ALLR
    $BSGM
    $MGRM

    CompanyDatePrice TargetRatingAnalyst
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Rallybio Corporation
    $RLYB
    4/9/2025Buy → Neutral
    H.C. Wainwright
    Monogram Technologies Inc.
    $MGRM
    12/9/2024$4.00Buy
    ROTH MKM
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Rani Therapeutics Holdings Inc.
    $RANI
    8/2/2024$17.00Outperform
    Oppenheimer
    Rani Therapeutics Holdings Inc.
    $RANI
    6/14/2024$15.00Buy
    Maxim Group
    Rani Therapeutics Holdings Inc.
    $RANI
    6/13/2024$10.00Buy
    Rodman & Renshaw
    Rallybio Corporation
    $RLYB
    5/15/2024Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Rallybio Corporation

    SCHEDULE 13G/A - Rallybio Corp (0001739410) (Subject)

    3/6/26 10:12:33 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Rallybio Corporation

    SCHEDULE 13G - Rallybio Corp (0001739410) (Subject)

    3/6/26 10:09:50 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    3/6/26 8:22:50 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

             Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Com

    3/6/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

    GLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement with Molteni Farmaceutici ("Molteni") for a proposed exclusive partnership covering the commercialization of AD04 in Europe. The collaboration framework, which is subject to execution of a final definitive agreement, sets forth the strategic and financial parameters of the planned partnership, covering clinical, regulatory, manufacturing, and commercial terms. Under the framework

    3/3/26 8:17:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Lieber Jonathan I sold $3,992 worth of shares (789 units at $5.06) and was granted 2,500 shares, increasing direct ownership by 71% to 4,115 units (SEC Form 4)

    4 - Rallybio Corp (0001739410) (Issuer)

    2/23/26 6:21:32 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mackay Martin

    4 - Rallybio Corp (0001739410) (Issuer)

    2/20/26 6:08:28 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunt Ronald

    4 - Rallybio Corp (0001739410) (Issuer)

    2/20/26 5:50:52 PM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rallybio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Rallybio from Buy to Neutral

    4/9/25 8:36:28 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Monogram Technologies with a new price target

    ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

    12/9/24 7:59:36 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Financials

    Live finance-specific insights

    View All

    Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

    Combined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505 million committed by a syndicate of leading healthcare institutional investors and mutual funds expected to fund operations through 2030 Companies to hold joint conference call on March 2, 2026 at 8:30 AM ET Rallybio Corporation (NASDAQ:RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into

    3/2/26 8:00:00 AM ET
    $RLYB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

         Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the third quarter ended September 30, 2025. "The third quarter of 2025 was another milestone period for Allarity as we ac

    11/14/25 9:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ADIL
    $ALLR
    $BSGM
    $MGRM
    Leadership Updates

    Live Leadership Updates

    View All

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

    – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Anomaly, Special Situations Funds, and Invus – – Appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the Board of Directors – – Cash runway expected to extend into 2028 – SAN JOSE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third

    11/6/25 4:30:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

    SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham ("Abe") Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from the Board of Directors. "We are thrilled to welcome Abe and Vasudev to our Board of Directors as we enter an exciting new era for Rani, highlighted by both our clinical-stage pipeline and expansion opportunities into high-value therapeutics from our rece

    10/23/25 4:01:45 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care